Oncotelic Therapeutics Highlights Partnership Strategy to Advance Pipeline and Boost Shareholder Value

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) provided a corporate update on Tuesday, emphasizing its partnership-driven strategy to advance its oncology and rare disease pipeline while enhancing shareholder value. The company highlighted its joint venture with GMP Biotechnology, which contributed to a $249.0 million increase in its balance sheet based on an independent third-party valuation, and said it is pursuing additional collaborations to support development and commercialization efforts.

Management noted that the approach is designed to advance multiple drug candidates in parallel while maintaining capital efficiency and unlocking the value of its intellectual property portfolio. Oncotelic is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, aiming to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.

For more information, visit the full press release at https://ibn.fm/Rv7Gc and the company's newsroom at https://ibn.fm/OTLC.